Altered expression of the receptor-ligand pair CXCR5/CXCL13 in B cells during chronic HIV-1 infection

Blood ◽  
2008 ◽  
Vol 112 (12) ◽  
pp. 4401-4410 ◽  
Author(s):  
Alberto Cagigi ◽  
Frida Mowafi ◽  
Linh V. Phuong Dang ◽  
Klara Tenner-Racz ◽  
Ann Atlas ◽  
...  

Abstract HIV-1 infection is associated with B-cell abnormalities, such as hypergammaglobulinemia, poor immunization responses, and loss of serologic memory. To determine whether altered expression of chemokine receptors and their ligands may play a role in B-cell dysfunctions during HIV-1 infection, the expression of CXC chemokine receptor 4 (CXCR4), CXCR5, and CC chemokine receptor 7 (CCR7) and their respective ligands on CD19+ B cells were examined in HIV-1–infected patients and controls. We report a decreased CXCR5 expression on B cells from patients (P < .05), a phenomenon associated with a low CD4 T-cell count (< 350 cells/μL). Interestingly, an increased expression of CXC chemokine ligand 13 (CXCL13), the ligand for CXCR5, was found in peripheral B cells from HIV-1–infected patients. Moreover, on B-cell activation in vitro, CXCL13 was secreted in culture. CXCL13+ B cells were also found in the lymph nodes of HIV-1–infected patients, but not in control tissue. B-cell migration toward CXCL13, CXCL12, and CC chemokine ligand 21 (CCL21), ligands for CXCR5, CXCR4, and CCR7 was also evaluated. In patients with a low CD4 T-cell count, migration toward all ligands was increased. Our findings indicate that altered expression of the chemokine receptor-ligand pair, CXCR5/CXCL13, may participate in the establishment of B-cell dysfunctions during HIV-1 infection.

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 4896-4896 ◽  
Author(s):  
Nathalie Burger ◽  
Andrea Haerzschel ◽  
Marion Leick ◽  
Tanja Nicole Hartmann ◽  
Julie Catusse ◽  
...  

Abstract Abstract 4896 Introduction: Chemokines are known to play an important role in the migration and survival of B-CLL cells. The non-signalling chemokine receptors, including DARC, D6 and CCX-CKR, have recently been shown to be involved in chemokine clearance and activity regulation. The human chemokine receptor CRAM is the most recently identified member of this atypical group. CRAM is expressed on B cells in a maturation-stage dependent manner, and to variable degrees on B-CLL cells. We have recently shown that it competitively binds CCL19 and that this binding is not followed by classical chemokine responses. CCL19 and its signalling receptor CCR7 are centrally involved in B cell localisation and maturation within the secondary lymphoid tissues. CCR7 is also highly expressed on B cells from CLL patients and mediates migration towards its ligands CCL19 and CCL21 which have been shown to be present at higher concentrations in serum of patients with lymphadenopathia compared to patients without. In this study we investigate the influence of CRAM on the CCL19 dependent responses of B-CLL cells and potential correlations to clinical data with a specific focus on lymphadenopathia. Results: We demonstrate that B cells from patients with B-CLL present high, but variable degrees of CCR7 and CRAM expression. Patients with compared to patients without lymphadenopathia show a higher CRAM expression level whereas the CCR7 expression is not significantly different. In single samples showing extremly high CRAM expression the migration towards CCL19 is reduced compared to patients with lower CRAM expression. These observations confirm results in the B-CLL cell line MEC-1 showing increased migration toward CCL19 when CRAM expression is reduced using CRAM-siRNA. On the other hand, CRAM seems to be a chemokine presenter as we can show that it does not degrade its chemokine ligand but presents it on the surface of polarised cell layers. Thus, we assume that CRAM plays a role for cell migration, possibly transmigration and cell localisation within lymph nodes of B-CLL cells. Conclusions: We show that CRAM can act as an integrator of different recruitment and activation factors. It is associated to CCR7 driven recruitment of B cells by regulating CCL19 availability. Expression of CRAM differs in B cell malignancies for which CCL19 and CCL21 have already been shown to be implicated in lymphadenopathia. We therefore suggest that CRAM is an additional player in the localisation and differentiation/maturation processes of malignant B cells of B-CLL patients. Disclosures: No relevant conflicts of interest to declare.


2002 ◽  
Vol 168 (10) ◽  
pp. 5117-5123 ◽  
Author(s):  
Ping Yu ◽  
Yang Wang ◽  
Robert K. Chin ◽  
Luisa Martinez-Pomares ◽  
Siamon Gordon ◽  
...  

PLoS ONE ◽  
2011 ◽  
Vol 6 (8) ◽  
pp. e22653 ◽  
Author(s):  
Peter Oballah ◽  
Britta Flach ◽  
Leigh A. Eller ◽  
Michael A. Eller ◽  
Benson Ouma ◽  
...  

1995 ◽  
Vol 25 (9) ◽  
pp. 2539-2543 ◽  
Author(s):  
Reem Al-Daccak ◽  
Bassam Damaj ◽  
Paul H. Naccache ◽  
Walid Mourad

2017 ◽  
Vol 12 (1) ◽  
pp. S809-S810
Author(s):  
Artjoms Spaks ◽  
Donats Breiva ◽  
Ilmars Tracums ◽  
Anastasija Bistrova ◽  
Krista Grigorovica ◽  
...  

2013 ◽  
Vol 85 (10) ◽  
pp. 1687-1691 ◽  
Author(s):  
Man-Qing Liu ◽  
Li Tang ◽  
Wen-Hua Kong ◽  
Ze-Rong Zhu ◽  
Jin-Song Peng ◽  
...  

AIDS ◽  
2006 ◽  
Vol 20 (16) ◽  
pp. 2033-2041 ◽  
Author(s):  
Marco Marziali ◽  
Wladimiro De Santis ◽  
Rossella Carello ◽  
Wilma Leti ◽  
Antonella Esposito ◽  
...  

Virology ◽  
1998 ◽  
Vol 244 (2) ◽  
pp. 542-551 ◽  
Author(s):  
Laurent Fritsch ◽  
Vincent Marechal ◽  
Véronique Schneider ◽  
Corinne Barthet ◽  
Willy Rozenbaum ◽  
...  
Keyword(s):  
B Cells ◽  
B Cell ◽  

Sign in / Sign up

Export Citation Format

Share Document